Biomolecules & Therapeutics

  • 제17권2호
  • /
  • Pages.138-143
  • /
  • 2009
  • /
  • 1976-9148(pISSN)
  • /
  • 2005-4483(eISSN)
한국응용약물학회 (The Korean Society of Applied Pharmacology)
권호 표지
DOI QR코드

DOI QR Code

The Basis of Different Sensitivities of Ovarian Cancer Cells to the Recombinant Adenoviral Vector System Containing a Tumor-Specific L-plastin Promoter and E. coli Cytosine Deaminase Gene as a Transcription Unit

  • 발행 : 2009.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

We have reported previously on a replication incompetent recombinant adenoviral vector, AdLPCD, in which the expression of cytosine deaminase gene (CD) is driven by the tumor-specific L-plastin promoter. AdLPCD vector had been evaluated for its efficacy of chemosensitization of ovarian cancer cells to 5-FC. In spite of the fact that ovarian cancer cells, i.e., OVCAR-3 and SK-OV-3, are capable for adenoviral transduction judged by LacZ reporter gene analysis, two cell lines demonstrated quite different sensitivities toward AdLPCD/5-FC system. In OVCAR-3 cells, infection of AdLPCD followed by exposure to 5-FC resulted in the suppression of cell growth with statistical significance. On the other hand, SK-OV-3 cells were more resistant to the CD/5-FC strategy compared with OVCAR-3 cells under the same condition. The object of study was to investigate factors that would determine the sensitivity to AdLPCD/5-FC. We evaluated conversion rate of 5-FC to 5-FU after infection of AdLPCD by HPLC analysis, $IC_{50}$ of 5-FU, the expression level of integrin receptors i.e., ${\alpha}v{\beta}3$ and ${\alpha}v{\beta}5$, and status of p53 in OVCAR-3 and SK-OV-3 cells. The results indicated that OVCAR-3 cells have few favorable features compared with SK-OV-3 cells to be more effective to the AdLPCD/5-FC strategy; higher level of ${\alpha}v{\beta}5$ integrin, higher rate of conversion of 5-FC into 5-FC, and lower $IC_{50}$ of 5-FU. The results suggest that the replacement of 5-FU with CD/5-FC in combination chemotherapy would be less toxic and much greater cytotoxicity than the conventional combination chemotherapy in some patients.

키워드

참고문헌

  1. Akbulut, H., Zhang, L., Tang, Y. and Deisseroth, A. (2003). Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon. Cancer Gene. Ther. 10, 388-395 https://doi.org/10.1038/sj.cgt.7700579
  2. Anderson, L., Kilstrup, M. and Neuhard, J. (1989). Pyrimidine, purine and nitrogen control of cytosine deaminase synthesis in Escherichia coli K12. Involvement of the glnG and purR genes in the regulation of codA expression. Arch. Microbiol. 152, 115-118 https://doi.org/10.1007/BF00456087
  3. Austin, E. A. and Huber, B. E. (1993). A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of E. coli cytosine deaminase. Mol. Pharmacol. 43, 380-387
  4. Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L. and Finberg, R. W. (1997). Isolation of a common receptor for cosackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323 https://doi.org/10.1126/science.275.5304.1320
  5. Chung. I. (2003). Cancer gene therapy: history and major developments. J. Toxicol. Pub. Health. 19, 247-257
  6. Chung, I. (2005). Chemosensitization of human ovarian carcinoma cells by a recombinant adenoviral vector containing L-plastin promoter fused to cytosine deaminase transcription unit. J. of Applied Pharmacol. 13, 143-149
  7. Chung, I. and Deisseroth, A. B. (2004). Recombinant adenoviral vector containing tumor-specific L-plastin promoter fused to cytosine deaminase gene as a transcription unit : Generation and Functional Test. Arch. Pharm. Res. 27, 633-639 https://doi.org/10.1007/BF02980163
  8. Chung, I., Schwartz, P. E., Crystal, R. G., Pizzorno, G., Leavitt, J. L. and Deisseroth, A. B. (1999). Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells. Cancer Gene. Ther. 6, 99-106 https://doi.org/10.1038/sj.cgt.7700017
  9. Garcia-Sanchez, F., Pizzorno, G., Fu, S. Q., Nanakorn, T., Krause, D. S., Liang, J., Adams, E., Leffert, J. J., Yin, L. H., Cooperberg, M. R., Hanania, E., Wang, W. L., Won, J. H., Peng, X. Y., Cote, R., Brown, R., Burtness, B., Giles, R., Crystal, R. and Deisseroth, A. B. (1998). Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. Blood 92, 672-682
  10. Glazer, R. I. and Lloyd, L. S. (1982). Association of cell lethality with incorporation of 5-fluorouracil and 5-fluoridine into nuclear RNA in human colon carcinoma cells in culture. Mol. Pharmacol. 21, 468-473
  11. Goldman, M. J. and Wilson, J. M. (1995). Expression of avb3 and avb5 integrin is necessary for efficient adenovirusmediated gene transfer in the human airway. J. Virol. 69, 5951-5958
  12. Graham, F. L. and Prevec, L. (1991). Manipulation of adenovirus vectors, Methods in molecular biology, Vol. 7, p109-128, E. J. Murray, The Human Press Inc., Clifton, NJ https://doi.org/10.1385/0-89603-178-0:109
  13. Higashiyama, M., Kodama, K., Yokouchi, H., Takami, K., Doi, O., Kobayashi, H., Tanisaka, K. and Minamigawa, K. (1998). Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs. J. Surg. Oncol. 68, 19-24 https://doi.org/10.1002/(SICI)1096-9098(199805)68:1<19::AID-JSO5>3.0.CO;2-O
  14. Hirschowitz, E. A., Ohwada, A., Pascal, W. R., Russi, T. J. and Crystal, R. G. (1995). In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum. Gene Ther. 6, 1055-1063 https://doi.org/10.1089/hum.1995.6.8-1055
  15. Huber, B. E., Austin, E. A., Good, S. S., Knick, V. C., Tibbels, S. and Richards, C. A., (1993). In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically codified to express cytosine deaminase. Cancer Res. 3, 4619-4626
  16. Jung, K., Kim, S., Lee, K., Kim, C. and Chung, I. (2007). Cytotoxic effect of a replication-incompetent adenoviral vector with cytosine deaminase gene driven by L-plastin promoter in hepatocellular carcinoma cells. Arch. Pharm. Res. 30, 770-777 https://doi.org/10.1007/BF02977641
  17. Kievit, E., Nyati, M. K., Ng, E., Stegman, L. D., Parsels, J., Ross, B. D., Rehemtulla, A. and Lawrence, T. S. (2000). Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res. 60, 6649-6655
  18. Kufe, D. W. and Major, P. P. (1981). 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J. Biol. Chem. 256, 9802-9805
  19. Lenz, H. J., Hayashi, K., Salonga, D., Danenberg, K. D., Danenberg, P. V., Metzger, R., Banerjee, D., Bertino, J. R., Groshen, S., Leichman, L. P. and Leichman, C. G. (1998). p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin. Cancer Res. 4, 1243-1250
  20. Moolten, F. L. (1994). Drug sensitivity (suicide) genes for selective cancer chemotherapy. Cancer Gene Ther. 1, 279-287
  21. Peng, X. Y., Won, J. H., Rutherford, T., Fujii, T., Zelterman, D., Pizzorno, G., Sapi, E., Leavitt, J., Kacinski, B., Crystal, R., Schwartz, P. and Deisseroth, A. (2001). The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Res. 61, 4405-4413
  22. Pritchard, D. M., Watson, A. J., Potten, C. S., Jackman, A. L. and Hickman, J. A. (1997). Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc. Natl. Acad. Sci. USA. 94, 1795-1799 https://doi.org/10.1073/pnas.94.5.1795
  23. Wickham, T. J., Filardo, E. J., Cheresh, D. A. and Nemerow, G. R. (1994). Integrin $\alpha v\beta3$ selectively promotes adenovirus mediated cell membrane permeabilization. J. Cell Biol. 127, 257-264 https://doi.org/10.1083/jcb.127.1.257
  24. Wickham, T. J., Mathias, P., Cheresh, D. A. and Nemerow, G. (1993). Integrins $\alpha v\beta3 and \alpha v\beta5$ promote adenovirus internalization but not virus attachment. Cell 73, 309-319 https://doi.org/10.1016/0092-8674(93)90231-E
  25. Yaginuma, Y. and Westphal, H. (1992) Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res. 52, 4196-4199
  26. Zhang, L., Akbulut, H., Tang, Y., Peng, X., Pizzorno, G., Sapi, E., Manegold, S. and Deisseroth, A. (2002). Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanoma. Mol. Ther. 6, 386-393 https://doi.org/10.1006/mthe.2002.0680